Changzhou Fangyuan Pharmaceutical Co. Ltd., of Changzhou, China, said it is the new site of the Chinese Academy of Engineering Wang Guangji Academic Workstation, which plans to sign a strategic cooperation agreement with the pharma and the China State Institute of Pharmaceutical Industry to develop aminoglycosides, antibacterial agents designed to reduce the side effects of antibiotics on the body. Fangyuan Pharma said its R&D team developed a preparation process for the generic drug, arbekacin sulfate, which is expected to go into production in 2018.